List of Excipients in Branded Drug CORTISPORIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	CORTISPORIN	neomycin sulfate, polymyxin b sulfate and hydrocortisone acetate	54868-1531	LIGHT MINERAL OIL
Physicians Total Care Inc	CORTISPORIN	neomycin sulfate, polymyxin b sulfate and hydrocortisone acetate	54868-1531	METHYLPARABEN
Physicians Total Care Inc	CORTISPORIN	neomycin sulfate, polymyxin b sulfate and hydrocortisone acetate	54868-1531	PETROLATUM
Physicians Total Care Inc	CORTISPORIN	neomycin sulfate, polymyxin b sulfate and hydrocortisone acetate	54868-1531	PROPYLENE GLYCOL

Cortisporin Excipient Strategy and Commercial Opportunities in Otic and Ophthalmic Anti-Infective Products

Last updated: August 23, 2026

Cortisporin is a legacy brand family rather than a single drug product. Its commercial value is tied to combinations of neomycin, polymyxin B and hydrocortisone, with different excipient systems for otic suspensions, ophthalmic suspensions and ointments. The strongest opportunities are preservative-free reformulation, improved suspension delivery, single-dose packaging, lower-irritancy excipients and 505(b)(2) products that address usability or tolerability limitations.

The brand has limited apparent exclusivity value. Generic and branded-generic competition, old active-ingredient combinations and the absence of meaningful modern market exclusivity shift the commercial focus toward formulation performance, device differentiation, manufacturing reliability and channel execution.

What is Cortisporin and which formulations are commercially relevant?

Cortisporin products combine antibacterial agents with a corticosteroid. The core formulation logic is to treat bacterial infection while reducing inflammation.

Product type	Active ingredients	Principal dosage form	Commercial formulation issue
Cortisporin Otic Suspension	Neomycin sulfate, polymyxin B sulfate, hydrocortisone	Multidose otic suspension	Resuspension, drop uniformity, microbial preservation and patient handling
Cortisporin Otic Solution	Neomycin sulfate, polymyxin B sulfate, hydrocortisone	Multidose otic solution	Solubilization, chemical stability and preservative tolerability
Cortisporin-TC Otic Suspension	Neomycin sulfate, polymyxin B sulfate, hydrocortisone and thonzonium bromide	Multidose otic suspension	Suspension stability and differentiation from standard Cortisporin
Cortisporin Ophthalmic Suspension	Neomycin sulfate, polymyxin B sulfate and hydrocortisone acetate	Ophthalmic suspension	Sterility, particle size, shake uniformity and ocular tolerability
Cortisporin Ophthalmic Ointment	Neomycin, polymyxin B and hydrocortisone	Sterile ophthalmic ointment	Greasiness, visual blurring, tube delivery and preservative avoidance

The exact inactive-ingredient profile varies by dosage form and product label. Commercial analysis should not treat “Cortisporin” as one excipient platform. The otic, ophthalmic and ointment products have different quality attributes, regulatory requirements and user preferences. FDA-approved labeling identifies the specific active and inactive ingredients for each product presentation (DailyMed, n.d.-a, n.d.-b).

What excipients are used in Cortisporin products?

Cortisporin formulations use conventional excipients selected for wetting, dispersion, viscosity control, isotonicity, preservation and semisolid delivery.

Otic suspension excipients

Typical functional categories include:

• Aqueous vehicle
• Glycerin or other tonicity and viscosity modifiers
• Polysorbate surfactants for wetting and dispersion
• Sodium chloride for tonicity adjustment
• Buffering or pH-adjustment agents
• Suspending agents
• Preservatives where used
• Packaging-compatible antioxidants or chelating agents where justified

For a suspension containing hydrocortisone or hydrocortisone acetate, the critical performance requirement is consistent dose delivery after shaking. Suspended active particles can settle during storage. A formulation that requires aggressive shaking, forms a hard sediment or delivers inconsistent drops creates a substitution opportunity.

Ophthalmic suspension excipients

Ophthalmic products impose tighter controls than otic products. Relevant excipient requirements include:

• Sterile aqueous vehicle
• Controlled particle size
• Low ocular irritation
• Appropriate osmolality
• Physiologically acceptable pH
• Effective antimicrobial preservation for multidose containers
• Compatibility with dropper geometry and container closure systems

Polysorbates, sodium chloride, citrate or phosphate buffers and preservatives may be used depending on the product. The final formulation must satisfy sterility, particulate, preservative-effectiveness and container-closure requirements. Excipient selection cannot be transferred directly from an otic formulation to an ophthalmic product.

Ophthalmic ointment excipients

Ophthalmic ointments commonly rely on mineral oil, white petrolatum or comparable sterile oleaginous bases. These excipients improve residence time but can cause blurred vision, affect patient acceptance and complicate precise dose delivery.

The commercial tradeoff is clear:

Ointment benefit	Ointment limitation
Longer ocular residence time	Blurred vision
No aqueous suspension settling	Greasy sensation
Potentially lower reliance on aqueous preservatives	Tube dose variability
Useful for nocturnal administration	Lower convenience than drops

Which excipient strategy offers the strongest commercial opportunity?

The strongest opportunity is a differentiated formulation that preserves the established active combination while improving use, tolerability or stability.

1. Preservative-free multidose or unit-dose products

Preservative-free delivery is the most commercially visible excipient opportunity, particularly for ophthalmic products and patients with ocular-surface sensitivity. A unit-dose vial eliminates the need for a multidose preservative system but increases packaging cost and manufacturing complexity.

Potential formats include:

• Single-use blow-fill-seal ampoules
• Unit-dose low-density polyethylene containers
• Preservative-free sterile suspension vials
• Dual-pack products for short treatment courses

A preservative-free product is commercially stronger when it has a defined target population, such as patients with preservative intolerance, recurrent exposure or compromised ocular surfaces. It is less compelling when the product is positioned only as a price-based generic.

2. Improved suspension technology

A suspension with rapid redispersion, low sedimentation and predictable drop delivery can support a differentiated product without changing the active ingredients.

Useful excipient levers include:

• Controlled particle-size distribution
• Low-irritancy wetting agents
• Structured vehicles with controlled yield stress
• Polymer suspending systems
• Density matching between particles and vehicle
• Reduced sediment compaction
• Optimized dropper aperture and bottle geometry

The formulation target is not maximum viscosity. Excessive viscosity can slow drop formation, impair patient dosing and reduce acceptance. The relevant design space is a vehicle that keeps particles suspended during normal handling while allowing rapid, consistent drop delivery after shaking.

3. Lower-irritancy preservative systems

Where a multidose package is required, a lower-irritancy preservation system may provide a market position against products containing older preservatives. Benzalkonium chloride has been associated with ocular-surface tolerability concerns, particularly with repeated exposure. A reformulation strategy may evaluate alternative preservatives, lower concentrations, preservative combinations or packaging that reduces contamination risk.

The regulatory burden is higher than a simple excipient substitution. The sponsor must establish antimicrobial effectiveness, preservative distribution, container compatibility, extractables and leachables, and product stability.

4. Improved otic residence time

Otic formulations can be differentiated through controlled viscosity and wetting rather than through aggressive penetration claims. Candidate excipient approaches include:

• Mucoadhesive polymers
• Glycerin-based viscous vehicles
• Controlled surfactant systems
• Non-irritating rheology modifiers
• Formulations that remain localized in the ear canal

The formulation must avoid excessive occlusion, discomfort and difficult removal. A viscous otic product may be commercially useful when it reduces dosing frequency, but the claim must be supported by clinical or pharmacokinetic evidence appropriate to the regulatory pathway.

5. Device-led differentiation

The dropper and container are part of the commercial product. Opportunities include:

• Calibrated drop delivery
• Inverted-use bottles
• Tamper-evident multidose systems
• Child-resistant packaging
• Unit-dose packs
• Packaging that limits microbial ingress
• Labels with prominent “shake well” instructions
• Improved bottle ergonomics for pediatric and elderly users

Device differentiation is potentially protectable through design, packaging or combination-product claims, even when the underlying active formulation has limited patent value.

What formulations are protected by Cortisporin patents?

Cortisporin’s commercial protection is unlikely to depend on a strong, current composition-of-matter patent estate. The active ingredients are old, and the major product concepts have been marketed for decades. The primary competitive barriers are more likely to be:

• Product-specific formulation patents, if still enforceable
• Manufacturing know-how
• Sterile suspension process controls
• Device or container patents
• Trademarks and brand recognition
• FDA-approved labeling
• Distribution relationships
• Quality-system performance

A current freedom-to-operate review should distinguish among:

1. Expired patents covering the active combination.
2. Expired or abandoned formulation patents.
3. Any live patents covering excipient ratios, particle-size controls, devices or manufacturing methods.
4. Orange Book-listed patents for the specific reference product.
5. Unlisted patents that may still create litigation risk but do not support an Orange Book patent certification.

The FDA Orange Book should be reviewed by NDA and active ingredient rather than by brand name alone. Old products may have limited or no currently listed patent protection. Absence of an Orange Book listing does not establish that no third-party patent risk exists (FDA, n.d.-a).

When does Cortisporin lose exclusivity?

Cortisporin is already a legacy product category in the United States. The relevant commercial question is not when the original brand loses exclusivity, but whether a new formulation can obtain independent regulatory and market protection.

Protection type	Relevance to Cortisporin
New chemical entity exclusivity	Not available for old active ingredients
Original drug patent	Generally historical and likely expired
Formulation patent	Possible for a specific new formulation, device or process
Method-of-use patent	Possible but narrow and dependent on approved labeling
Orphan exclusivity	Not applicable to ordinary Cortisporin indications
Pediatric exclusivity	Product-specific and not a durable commercial strategy
180-day generic exclusivity	Relevant only to qualifying ANDA Paragraph IV litigation
3-year 505(b)(2) exclusivity	Potentially relevant for a new clinical investigation or formulation change
5-year NCE exclusivity	Not available for the established combination

A new sponsor could seek three-year exclusivity through a 505(b)(2) application if it conducts new clinical investigations essential to approval and obtains approval for a change such as a new dosage form, route, formulation or indication. The exclusivity would not block all products using the same active ingredients, and it would not recreate the protection of an NCE (FDA, n.d.-b).

What FDA pathway is most suitable for a new Cortisporin product?

The pathway depends on whether the product is pharmaceutically equivalent to an approved reference product.

ANDA pathway

An ANDA is most suitable when the proposed product matches the reference product in active ingredients, dosage form, strength, route and relevant performance characteristics. The applicant must demonstrate pharmaceutical equivalence and bioequivalence or satisfy applicable product-specific requirements.

For suspensions, comparative performance can be more complex than for simple solutions. Particle size, redispersibility, rheology and delivered dose may affect equivalence.

505(b)(2) pathway

A 505(b)(2) application is more appropriate when the sponsor changes:

• Excipients in a way that requires additional clinical support
• Dosage form
• Container or delivery system
• Dosing frequency
• Route or site of administration
• Indication
• Preservative status with a clinically meaningful tolerability claim

A 505(b)(2) product can create a differentiated commercial position but will generally require a stronger evidence package and more extensive FDA interaction than a conventional ANDA.

Which companies are challenging Cortisporin?

Competition is fragmented across branded generics, ophthalmic and otic manufacturers, specialty generic companies and contract manufacturers. The relevant competitors are not limited to products carrying the Cortisporin name.

Competitive categories include:

• Neomycin/polymyxin B/hydrocortisone otic suspensions
• Neomycin/polymyxin B/hydrocortisone otic solutions
• Ciprofloxacin-based otic products
• Ofloxacin otic products
• Tobramycin/dexamethasone ophthalmic products
• Neomycin/polymyxin B/dexamethasone ophthalmic products
• Antibiotic-steroid products using newer fluoroquinolone combinations

Ciprofloxacin and ofloxacin products compete particularly strongly in otic infections because they offer different dosing, safety and resistance considerations. Ophthalmic competition is broader because clinicians can select antibiotic-steroid combinations with different corticosteroids, preservatives, dosage forms and dosing schedules.

What generic launch risks exist for Cortisporin?

A generic launch faces low active-ingredient barriers but meaningful execution risks.

Technical risks

• Inconsistent suspension redispersion
• Dose nonuniformity between early and late bottle withdrawals
• Particle growth during storage
• Hydrocortisone or hydrocortisone acetate instability
• Preservative loss through container interaction
• Drop-size variability
• Sterility failures
• Ointment phase separation
• Extractables and leachables from plastic packaging

Regulatory risks

• Failure to match reference-product quality attributes
• Inadequate bioequivalence justification
• Unacceptable inactive-ingredient differences for ophthalmic use
• Labeling deviations
• Inadequate preservative-effectiveness data
• Failure to establish container-closure integrity

Commercial risks

• Low reimbursement and price erosion
• Limited wholesaler access
• Short product life if multiple ANDAs launch together
• Brand substitution by lower-cost alternatives
• Prescriber preference for fluoroquinolone products
• Small market size for preservative-free specialty presentations

How strong is the patent estate for Cortisporin?

The patent estate is likely weak as a barrier to conventional generic entry and stronger only around newly engineered products.

Asset category	Expected strategic strength
Active-ingredient combination	Low; legacy actives
Basic aqueous suspension	Low to moderate; vulnerable to design-around
Preservative system	Moderate if narrowly claimed and technically enabled
Particle-size and rheology profile	Moderate; can support formulation differentiation
Sterile manufacturing process	Moderate; often protected more effectively as trade secret
Single-dose packaging	Moderate to strong if paired with device claims
Delivery device	Moderate to strong depending on claim scope
New clinical indication	Potentially moderate, but method-of-use claims are narrow
Brand and trademark	Commercially useful but not equivalent to patent exclusivity

The most defensible strategy is a layered portfolio covering formulation composition, critical quality attributes, manufacturing parameters, container closure and device geometry. A single broad excipient patent is less likely to withstand design-around than a portfolio tied to measurable performance characteristics.

What licensing opportunities exist in Cortisporin reformulation?

Licensing opportunities are more likely to involve enabling technology than the historical Cortisporin brand.

Potential targets include:

• Preservative-free multidose packaging
• Sterile blow-fill-seal manufacturing
• Ophthalmic suspension stabilization
• Low-irritancy preservative systems
• Mucoadhesive otic vehicles
• Calibrated dropper technology
• Contract sterile filling
• Particle-engineering platforms
• Analytical methods for suspension uniformity

A license should be evaluated against four commercial questions:

1. Does the technology reduce a measurable quality or usability problem?
2. Can it support a 505(b)(2) exclusivity position?
3. Is the manufacturing process scalable at generic-market price points?
4. Can the technology be used across multiple anti-infective or corticosteroid products?

A platform that works only for Cortisporin may have limited return. A platform that can be applied to antibiotic-steroid, NSAID, glaucoma and dry-eye products has stronger licensing value.

How should manufacturers prioritize Cortisporin commercial opportunities?

Highest-priority opportunity

A preservative-free, unit-dose ophthalmic product with improved suspension redispersion and clear positioning for ocular-surface tolerability offers the strongest differentiation. Its weakness is cost, since unit-dose packaging and sterile fill-finish reduce margin.

Medium-priority opportunity

An otic suspension with improved drop uniformity, lower sedimentation and more convenient packaging could compete effectively in primary care and ENT channels. The product would need a clear value proposition because otic generic pricing is competitive.

Lower-priority opportunity

A conventional reformulation with a minor excipient substitution and no improved patient outcome is unlikely to justify a premium or meaningful exclusivity. It may still support an ANDA if the development cost is low, but the commercial upside is limited.

What is the revenue exposure and market outlook?

Cortisporin revenue is exposed to substitution from generic antibiotic-steroid products and therapeutic alternatives. The main revenue risks are price compression, formulary substitution and declining reliance on older aminoglycoside-containing products in some clinical settings.

Commercial upside is more likely in niche segments:

• Preservative-sensitive ophthalmic patients
• Pediatric and caregiver-administered otic products
• ENT practices seeking improved handling
• Hospital and ambulatory surgery channels
• Products with reliable sterile unit-dose supply
• Markets where legacy formulations have inconsistent availability

Revenue forecasting should separate product categories. Ophthalmic products may support higher differentiation and pricing, while otic products may offer broader volume but lower gross margin. The model should include launch timing, reference-product availability, reimbursement, pharmacy substitution and contract-manufacturing capacity.

Key Takeaways

• Cortisporin is a family of otic and ophthalmic antibiotic-steroid formulations, not one uniform product.
• The active ingredients are old, so conventional patent-based exclusivity is limited.
• The most valuable formulation opportunities involve preservative-free delivery, suspension uniformity, lower irritation and improved packaging.
• An ANDA is appropriate for a close generic equivalent; a 505(b)(2) pathway may support a materially differentiated formulation.
• Otic products offer volume opportunities but face strong price competition.
• Ophthalmic products offer stronger opportunities for premium positioning through preservative-free packaging and improved tolerability.
• The best intellectual-property strategy combines excipient composition, particle-size and rheology limits, manufacturing controls, container closure and device claims.
• Manufacturing capability, sterile fill-finish access and reliable suspension analytics may be more important than historical Cortisporin patent rights.

FAQs

Can a preservative-free Cortisporin product obtain FDA exclusivity?

Potentially. A preservative-free product may qualify for three-year 505(b)(2) exclusivity if approval depends on new clinical investigations conducted or sponsored by the applicant. The exclusivity would be product- and approval-specific.

Is thonzonium bromide an excipient in Cortisporin-TC?

No. Thonzonium bromide is an active ingredient in Cortisporin-TC, not an inactive excipient. It should be analyzed separately in regulatory, patent and bioequivalence assessments.

Can a company patent a new Cortisporin excipient combination?

Yes, if the combination is novel, nonobvious and supported by evidence of a technical advantage. Claims based only on routine substitution of known ophthalmic or otic excipients are vulnerable to invalidity and design-around challenges.

Are ophthalmic and otic Cortisporin products interchangeable?

No. They have different labeling, sterility expectations, excipient constraints, administration sites and regulatory requirements. An otic formulation cannot be assumed to be suitable for ophthalmic use.

What is the main manufacturing barrier for a generic Cortisporin suspension?

The principal barrier is reproducible sterile suspension performance. The manufacturer must control particle size, settling, redispersion, dose uniformity, preservative performance, container compatibility and delivered drop volume throughout shelf life.

References

1. DailyMed. (n.d.-a). Cortisporin otic suspension: Neomycin and polymyxin B sulfates and hydrocortisone acetate labeling. U.S. National Library of Medicine.

2. DailyMed. (n.d.-b). Cortisporin ophthalmic suspension and ointment labeling. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov

4. U.S. Food and Drug Administration. (n.d.-b). Applications covered by section 505(b)(2). https://www.fda.gov

5. U.S. Pharmacopeia. (n.d.). General chapter <771>: Ophthalmic products. United States Pharmacopeial Convention.

6. U.S. Food and Drug Administration. (n.d.-c). Inactive ingredient database. https://www.fda.gov